RxDoctor Payments Data

Stephen Rappaport, MD

Internal Medicine · Indianapolis, INNPI 1124248935

Payments from drug & device makers

$7,567in general payments, 2019–2025

Across 45 payments — averaging $168.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$6K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$927
  • Sunovion Pharmaceuticals Inc.$194
  • AbbVie$139
  • Lilly USA, LLC$72
  • Exact Sciences$57
  • plus $374 from 10 others

What the payments were for

  • Consulting fees$5,68775%
  • Travel & lodging$99713%
  • Food & beverage$88412%

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,567 in reported general payments places this provider in the 90th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$6,983
Medicare patients
32
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban179$55,667
XareltoRivaroxaban69$19,696
Risperidone ErRisperidone Microspheres15$18,550
JanuviaSitagliptin Phosphate37$13,863
MyrbetriqMirabegron33$10,823
JardianceEmpagliflozin29$8,997
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$7,594
TradjentaLinagliptin27$7,179
CreonLipase/Protease/Amylase14$6,856
Atorvastatin Calcium304$5,028
Alphagan PBrimonidine Tartrate12$4,983
EntrestoSacubitril/Valsartan17$4,516
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$4,038
Enoxaparin Sodium41$3,565
Pantoprazole Sodium95$3,357

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$35$13,86337 claims
AbbVieCreon, Alphagan P$139$11,83926 claims
GSKTrelegy Ellipta$55$7,59413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,747 internal medicine providers in Indiana.

Other internal medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →